SEC Form 4 · accession 0001192482-18-000276
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Federici
Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 7, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.30 | Jun 6, 2018 | A | 15,000 | A | — | Jun 6, 2028 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option vests upon the earlier of (i) June 6, 2019, or (ii) the day before the 2019 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc.